Medical Affairs Specialist Elanco Animal Health University Place, Washington, United States
Disclosure(s):
Chris George, DVM: No relevant disclosure to display
This program provides an overview of canine parvovirus (CPV) and Elanco’s Canine Parvovirus monoclonal antibody (CPMA). This discussion includes a brief review of disease state for CPV, standard of care inpatient and outpatient treatment options, and a review of multiple treatment options discussed in recent literature. An updated review of recent studies involving CPMA will also be provided.
Learning Objectives:
Recognize the impact of CPV on the patient, hospital, and owner.
Understand standard of care inpatient and outpatient treatment options.
Learn about recent treatment options discussed in the literature including a targeted Canine Parvovirus Monoclonal Antibody (CPMA) for CPV treatment.
.jpg "Chris George, DVM (he/him/his) photo")
